[
  {
    "vignette_index": 927,
    "input": "Glomerulonephritis END",
    "output": "THINKING: Use systematic clinical reasoning to develop your treatment plan for glomerulonephritis with the background of CKD stage 2. STEP 1 - DIAGNOSIS CONFIRMATION & SEVERITY ASSESSMENT: - Primary diagnosis confidence: Moderate to high, based on clinical presentation and known CKD stage 2, but requires confirmation with labs. - Severity classification: Mild to moderate, with signs of hematuria, proteinuria, bilateral ankle swelling, and systemic symptoms suggesting active renal involvement but no evidence of severe AKI or uremia yet. - Urgency level: Routine care, but with a need for prompt evaluation to prevent progression. - Differential considerations still requiring monitoring: Possible ongoing hematuria and systemic symptoms suggest active glomerular inflammation or secondary processes.  STEP 2 - EVIDENCE-BASED TREATMENT SELECTION: - First-line treatment per guidelines: Control of underlying inflammation (if active), blood pressure management, and supportive renal care. - Supporting evidence: Evidence supports immunosuppressive therapy if active glomerulonephritis is confirmed, along with supportive measures to reduce further renal damage. - Patient-specific considerations: Her underreporting suggests need to clarify symptoms, and existing CKD influences careful medication selection and blood pressure targets. - Contraindications or cautions: Avoid nephrotoxic agents; monitor for infections if immunosuppressants are used.  STEP 3 - PHARMACOLOGICAL INTERVENTIONS: - Primary medication choice: ACE inhibitor (e.g., lisinopril 10-20 mg daily) to reduce proteinuria and protect renal function. - Rationale for selection: ACE inhibitors are first-line for CKD with proteinuria, proven to slow progression. - Expected timeline for improvement: Partial reduction in proteinuria and BP control within 4-6 weeks; systemic symptoms may improve gradually. - Key side effects to monitor: Hyperkalemia, cough, hypotension, and worsening renal function. - Alternative medications if first-line fails: ARBs (e.g., losartan), or combination therapy if tolerated and indicated.  STEP 4 - NON-PHARMACOLOGICAL INTERVENTIONS: - Primary non-drug interventions: Dietary salt restriction (<2 g/day), adequate hydration, weight management. - Patient education priorities: Recognizing symptoms of worsening renal function, importance of medication adherence, and avoiding nephrotoxic substances. - Lifestyle modifications: Low-sodium diet, smoking cessation if applicable, regular gentle exercise. - Behavioral interventions: Stress management and emotional support to improve adherence and address emotional distress.  STEP 5 - MONITORING & FOLLOW-UP STRATEGY: - Follow-up timeline: Re-evaluate in 2-4 weeks after initiating or adjusting therapy; more frequent if symptoms worsen. - Monitoring parameters: BP, weight, edema, urine dipstick for hematuria and protein; serum potassium, creatinine, BUN every 1-2 months initially. - Red flag symptoms: Rapid worsening of edema, hematuria, increase in serum creatinine, signs of infection or hypotension. - Treatment response assessment: Reduction in hematuria/proteinuria, stabilization or improvement of renal function, symptom control.  STEP 6 - PATIENT COMMUNICATION STRATEGY: - Communication approach: Use simple, clear language, ensure understanding, and validate concerns. Encourage questions despite her withholding style. - Addressing patient concerns: Reassure about the importance of monitoring and treatment, address emotional distress, and involve her in decision-making. - Adherence strategies: Provide written summaries, set achievable goals, and schedule regular follow-up. - Family involvement: With her consent, involve trusted family members to support adherence and monitoring.  STEP 7 - COORDINATION & REFERRALS: - Specialist referrals needed: Nephrologist consultation within 2-4 weeks for confirmation of diagnosis and management plan. - Other healthcare team members: Possible dietitian for renal-friendly diet, mental health support if needed. - Community resources: Education materials from kidney foundations, support groups for chronic kidney disease. - Insurance/cost considerations: Confirm medication coverage, provide assistance programs if needed.\nANSWER: Based on the diagnosis of glomerulonephritis, I recommend a comprehensive treatment approach that combines evidence-based medical management with patient-centered care strategies. The treatment plan includes blood pressure control with ACE inhibitors, dietary modifications, and close monitoring of renal function and symptoms, tailored to her CKD stage 2 background. Initial management focuses on stabilizing her condition, preventing further renal damage, and addressing systemic symptoms. Follow-up will involve regular labs, clinical assessments, and collaboration with a nephrologist. Patient education will emphasize symptom recognition, medication adherence, and lifestyle changes. This approach aims to slow disease progression, alleviate symptoms, and improve her quality of life while minimizing risks.  IMPLEMENTATION GUIDANCE: - Immediate actions (today): Review current medications, order baseline labs (serum creatinine, BUN, electrolytes, urinalysis), and provide dietary counseling. - Short-term goals (1-4 weeks): Initiate ACE inhibitor therapy, ensure patient understands medication importance, and schedule follow-up for lab results. - Long-term objectives (3-6 months): Achieve blood pressure targets, reduce proteinuria, and evaluate for additional immunosuppressive therapy if indicated. - Patient handout summary: Clarify her diagnosis, medication plan, lifestyle recommendations, warning signs to monitor, and follow-up schedule.",
    "gold_diagnosis": "Chronic kidney disease, stage 2"
  }
]